U.S. Water Utilities Stock News

If you are wondering whether Tenet Healthcare's current share price still offers value, this article walks through what the numbers say and how to think about the stock in practical terms. Tenet Healthcare recently closed at US$189.49, with a flat 7 day return, a 5.9% decline over 30 days, a 5.0% decline year to date, and longer term returns of 32.3% over 1 year, 227.5% over 3 years and 280.0% over 5 years. Recent coverage of Tenet Healthcare has focused on its position as a large US...

Concentra Group Holdings Parent (CON) has drawn attention after reporting preliminary Q4 and full year 2025 results that exceeded its earlier guidance, along with fresh 2026 outlook figures and updated investor materials. See our latest analysis for Concentra Group Holdings Parent. The latest guidance and buyback update come after a period where the 30 day share price return of 8.22% and year to date share price return of 11.28% contrast with a 1 year total shareholder return decline of...

If you are wondering whether PTC at around US$153 per share still makes sense for your portfolio, it helps to look closely at what the current price might be implying about the company. The stock has seen a 6.8% decline over the last 7 days, a 12.5% decline over 30 days and is down 9.8% year to date, with a 20.1% decline over the last year, although the 3 year and 5 year returns sit at 16.0% and 10.2% respectively. These moves come as investors continue to reassess software names in general...

Carpenter Technology (CRS) opened Q2 2026 with total revenue of US$728 million, basic EPS of US$2.10 and net income excluding extra items of US$105.3 million. This put fresh numbers on a year in which trailing twelve month EPS reached US$8.67 on revenue of US$2.9 billion and net income of US$434.7 million. Over the past year, the company has seen quarterly revenue move from US$676.9 million in Q2 2025 to US$728 million in Q2 2026, while basic EPS stepped up from US$1.67 to US$2.10 and...

Earlier this week, TechnipFMC’s board authorized a US$2.00 billion share repurchase plan, coinciding with heavy institutional activity that made the stock one of the most actively traded names in Euronext pre-market dealings. The scale of the buyback and concentration of institutional flows highlight how capital allocation decisions can quickly reshape liquidity and trading patterns around the company. With TechnipFMC’s new US$2.00 billion buyback at the center of attention, we’ll assess how...

CSG Systems International (NasdaqGS:CSGS) has extended its multi year contract with DISH Network to provide billing and payment platform services. The agreement continues a decades long relationship and is set to run through 2030. The renewal supports DISH Network’s customer experience goals while keeping CSG at the core of its connectivity operations. For investors watching NasdaqGS:CSGS, this long term renewal with a major client comes as the stock trades at $79.65, with a 1 year return...

Perspective Therapeutics recently reported updated interim data from its ongoing Phase 1/2a trial of lead radiopharmaceutical candidate VMT-α-NET, indicating sustained anti-tumor activity, and issued a business update outlining clinical priorities and manufacturing expansion plans. This combination of early clinical signals and investment in production capacity highlights how the company is positioning VMT-α-NET as a core asset in its radiopharmaceutical pipeline. We’ll now examine how the...

Why Neogen (NEOG) is on investors’ radar today Neogen (NEOG) has captured attention after a sharp move in its share price over the past month, with recent performance prompting investors to reassess how the company’s food and animal safety business is currently valued. See our latest analysis for Neogen. That sharp 30 day share price return of 44.82% and 90 day gain of 65.48% contrast with a weaker picture over longer horizons, where the 1 year total shareholder return is a decline of 11.06%...

NewAmsterdam Pharma (NAMS) is back in focus after management reported positive Phase 3 data for its lead drug obicetrapib in cardiovascular and Alzheimer’s disease indications and highlighted an upcoming European regulatory decision. See our latest analysis for NewAmsterdam Pharma. Despite the recent positive clinical headlines, NewAmsterdam Pharma’s 7 day share price return of 9.68% and 90 day share price return of 17.15% point to cooling momentum, while its 1 year total shareholder return...

If you are wondering whether California Water Service Group is reasonably priced or offering hidden value at around US$44.47 per share, this article walks through what the numbers are actually saying. The stock is roughly flat over the last week with a 1.2% decline, modestly positive over the past month at 2.1%, and up 3.5% year to date. However, the 3 year and 5 year returns of 25.5% and 12.2% declines hint at a mixed longer term experience. Recent coverage has focused on California Water...

Ryman Hospitality Properties (RHP) caught investor attention after refinancing its revolving credit facility, lifting total capacity to US$850 million and extending the maturity to January 2030 while keeping pricing largely unchanged. See our latest analysis for Ryman Hospitality Properties. The refinancing headlines come after a mixed stretch for the stock, with a 1-day share price return of 1.26% at US$94.66, set against a 90-day share price return of 8.92% and a 1-year total shareholder...

Event-driven snapshot PennyMac Mortgage Investment Trust (PMT) has recently drawn investor attention after its US$13.51 last close, with returns over the past month and past 3 months inviting a closer look at this mortgage-focused REIT. See our latest analysis for PennyMac Mortgage Investment Trust. Looking beyond the recent move to US$13.51, the 30 day share price return of 7.48% and 90 day share price return of 12.21%, alongside a 1 year total shareholder return of 19.06%, point to momentum...

Global-E Online (GLBE) is back in focus after management moved closer to GAAP profitability, highlighted expanding free cash flow, and approved a US$200 million share repurchase program, while flagging fresh tariff and customs related risks. See our latest analysis for Global-E Online. The latest earnings update and buyback news arrive after a tougher stretch for investors, with a 1-year total shareholder return showing a 39.28% decline and a 3-year total shareholder return showing a 12.46%...

Independent Bank Corporation ( NASDAQ:IBCP ) stock is about to trade ex-dividend in three days. Typically, the...

Campbell's (CPB) stock has faced a mixed stretch recently, with gains over the past week but declines over the past month and over the past 3 months, prompting fresh questions about how its current valuation lines up with fundamentals. See our latest analysis for Campbell's. At a share price of US$27.01, Campbell's has seen short term momentum soften, with a 30 day share price return of 3.74% decline and a 90 day share price return of 10.36% decline, while the 1 year total shareholder return...

Hyatt Hotels Corporation recently reported a record development pipeline of about 148,000 rooms at year-end 2025 and disclosed a new class action lawsuit in California alleging multiple labor code violations. The company also appointed industry veteran Maria Zarraluqui to a newly created senior role to accelerate growth in its all-inclusive resort collection, signaling a continued focus on expanding this portfolio. We will now examine how Hyatt’s record room pipeline and emphasis on...

Aflac Incorporated ( NYSE:AFL ) has announced that it will be increasing its dividend from last year's comparable...

If you are looking at Ocular Therapeutix and wondering whether the recent share price reflects fair value, this article will walk you through what the numbers are actually saying. The stock has been volatile, with a 10.5% decline over the last 7 days and an 18.4% decline over the last 30 days, yet it still shows a 27.9% return over 1 year and a 134.7% return over 3 years, compared to a 47.4% decline over 5 years. These mixed returns sit against a backdrop of ongoing development in ophthalmic...

One Stop Systems, Inc. recently announced a past initial order worth US$1,100,000 from a top-tier aerospace prime contractor to deliver 200 ADB-10G ruggedized Ethernet switches for next-generation in-flight entertainment systems, scheduled for delivery by the fourth quarter of 2026. The company also indicated that this secure, Linux-based platform for in-flight entertainment management and redundancy could generate more than US$6.50 million in revenue over five years, underscoring the...

Event overview Gemini Space Station (GEMI) shares have come under pressure recently, with the stock showing negative returns over the past month and past 3 months, drawing investor attention to its crypto focused business model and fundamentals. See our latest analysis for Gemini Space Station. At a share price of $8.27, Gemini Space Station’s recent moves include a 1 day share price return of 9.38% decline and a 90 day share price return of 54.96% decline, suggesting momentum has been fading...

If you are wondering whether Silgan Holdings at around US$42.71 is offering good value today, you are not alone. The stock’s current price invites a closer look at what you are actually paying for. The share price is up 5.1% over the last 30 days, even though the 1 year return sits at a 22.6% decline and the 3 year return at an 18.8% decline. This may have investors reassessing both its growth potential and its risks. Silgan has recently been in focus around its position in packaging and...

Synchrony Financial’s recently reported fourth-quarter 2025 results showed net interest income rising to US$4,761 million and net income of US$751 million, alongside net charge-offs of US$1,367 million and continued capital returns via common and preferred dividends plus sizeable share repurchases. The quarter underscored a tension between strong purchase volumes and digital growth, including the rapidly scaling Walmart OnePay program, and a cautious 2026 outlook shaped by consumer spending...

Without a clear news headline driving attention to Viper Energy (VNOM) today, you might still be looking at the stock after its recent performance and valuation signals caught your eye. See our latest analysis for Viper Energy. At a share price of $41.99, Viper Energy’s recent 7 day share price return of 6.9% and 90 day share price return of 11.79% contrast with a 1 year total shareholder return of a 3.77% decline. This suggests short term momentum, while longer term holders have not yet seen...

Why this Eylea biosimilar settlement matters for Alvotech (ALVO) Alvotech (ALVO) has reached a worldwide licensing and settlement agreement with Regeneron and Bayer over its aflibercept biosimilar, securing rights to manufacture and supply the product across key global markets. The deal sets out specific launch windows from early 2026 in the United Kingdom, Canada, Japan and the European Economic Area, with a previously agreed fourth quarter 2026 license entry date for the U.S., subject to...